重组人血管内皮抑制素注射液持续静脉泵注联合同步放化疗治疗中晚期肺鳞癌的疗效

Therapeutic effect of recombinant human endostatin injection with continuous intravenous pumping combined with concurrent chemoradiotherapy on middle and advanced lung squamous cell carcinoma

目的观察重组人血管内皮抑制素注射液持续静脉泵注联合同步放化疗治疗中晚期肺鳞癌的临床疗效。方法选取2015年1月—2020年12月中国人民解放军第970医院收治住院的中晚期肺鳞癌患者50例,按照随机数字表法分为联合组和对照组,每组25例。对照组给予肺癌及纵隔转移淋巴结局部放疗,每周5次,同时给予长春瑞滨+顺铂全身化疗2个周期,放疗结束3周后再给予4个周期全身化疗。联合组在对照组治疗的基础上于每次化疗前4 d给予重组人血管内皮抑制素注射液持续静脉泵注。比较2组患者近期疗效、生存质量改善率和不良反应。结果联合组患者客观缓解率为60.00%,高于对照组的32.00%(χ^(2)=3.945,P=0.047);联合组与对照组患者疾病控制率比较差异无统计学意义(80.00%vs.64.00%,χ^(2)=1.587,P=0.208);联合组患者生存质量改善率为76.00%,高于对照组的48.00%(χ^(2)=4.160,P=0.041);2组患者各项不良反应发生率比较差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素注射液持续静脉泵注联合同步放化疗治疗中晚期肺鳞癌近期临床疗效显著,可提高客观有效率,改善生存质量,且未明显增加不良反应。

Objective To observe the clinical effect of recombinant human endostatin injection with continuous intravenous pumping combined with concurrent chemoradiotherapy in the treatment of middle and advanced lung squamous cell carcinoma.Methods Fifty patients with middle and advanced lung squamous cell carcinoma admitted to the Chinese PLA No.970 Hospital from January 2015 to December 2020 were selected and divided into combined group and control group according to random number table method,with 25 cases in each group.Control group was given local radiotherapy for lung cancer and mediastinal metastatic lymph nodes,5 times a week,and vinorelbine+cisplatin systemic chemotherapy for 2 cycles,and then 4 cycles of systemic chemotherapy 3 weeks after the end of radiotherapy.Combined group was given continuous intravenous pumping of recombinant human endostatin injection 4 days before each chemotherapy on the basis of the treatment of control group.The short-term efficacy,improvement rate of quality of life and adverse reactions were compared between the two groups.Results The objective remission rate of the combined group was 60.00%,which was higher than 32.00%of the control group(χ^(2)=3.945,P=0.047).There was no significant difference in disease control rate between the combined group and the control group(80.00%vs.64.00%,χ^(2)=1.587,P=0.208).The improvement rate of quality of life in combination group was 76.00%,which was higher than 48.00%in control group(χ^(2)=4.160,P=0.041).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant human endostatin injection with continuous intravenous pumping combined with concurrent chemoradiotherapy has significant clinical efficacy in the near term in the treatment of middle and advanced lung squamous cell carcinoma,which can improve objective effective rate and quality of life,and without significantly increasing adverse reactions.